Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lysogene

News headline image
Lysogene Announces the Extension of Deadline for the Submission of Offers
From Lysogene
Via Business Wire
News headline image
Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
From Lysogene
Via Business Wire
News headline image
Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings
From Lysogene
Via Business Wire
News headline image
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
From Lysogene
Via Business Wire
News headline image
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
From Lysogene
Via Business Wire
News headline image
Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022
From Lysogene
Via Business Wire
News headline image
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
From Lysogene
Via Business Wire
News headline image
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
From Lysogene
Via Business Wire
News headline image
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
From Lysogene
Via Business Wire
News headline image
Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations
From Lysogene
Via Business Wire
News headline image
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
From Lysogene
Via Business Wire
News headline image
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022
From Lysogene
Via Business Wire
News headline image
Lysogene Provides Medical Update
From Lysogene
Via Business Wire
News headline image
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
From Lysogene
Via Business Wire
News headline image
Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)
From Lysogene
Via Business Wire
News headline image
Lysogene Awarded Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program
From Lysogene
Via Business Wire
News headline image
Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021
From Lysogene
Via Business Wire
News headline image
Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
From Lysogene
Via Business Wire
News headline image
Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis
From Lysogene
Via Business Wire
News headline image
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
From Lysogene
Via Business Wire
News headline image
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
From Lysogene
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.